Skip to main content

Appropriate Dosage Of Unfraction Heparin And Low Molecular Weight Heparin In Hemodialysis Patients

Appropriate Dosage Of Unfraction Heparin And Low Molecular Weight Heparin In Hemodialysis Patients

[Article in Chinese] Xiao Q, Sun XF, Zhang D, Ma ZF, Wu MG, Wang H, Chen XM. Institute of Nephrology, General Hospital of Chinese People's Liberation Army, Beijing 100853, China.

 

Abstract OBJECTIVE: To investigate the appropriate dose of unfraction heparin and low molecular weight heparin (LMWH) in hemodialysis patients.

 

METHODS: Thirty-eight hemodialysis patients were enrolled and randomly allocated into four groups.The initial bolus dose for the Low-dose (LH, n = 10) and high-dose heparin (HH, n = 10) groups were 35 U/kg and 55 U/kg, respectively.The repeated maintenance dose for both groups were 10 U/kg.h and 16 U/kg.h, respectively. Fragmin were administered as single bolus (60 U/kg or 80 U/kg) at 30 minutes before hemodialysis in Low-dose LMWH(LLMWH, n = 10) and High-dose LMWH (HLMW, n = 8) group, respectively. Furthermore, the dialysis circuits in LUFH and LLMWUFH groups were primed with with 4 mg/dl heparinized saline before hemodialysis. Glass bead active clotting time (gbACT), clot rate (CR) and platelet function (PF) were examined using Sonoclot analysator at 0 h, 2 h and the end of hemodialysis at the arterial circuit and 2 h at the venous circuit. RESULTS: (1) LH and LUFH: the increase of gbACT and decrease of CR at the arterial circuit and the venous circuit at 2 h of hemodialysis were significant compared with baseline. While they recovered at the end of hemodialysis. No difference between the two groups at different time points was found, either. (2) LLMWH: No change were found in gbACT during hemodialysis. CR at the arterial circuit and the venous circuit were significantly decreased at 2 h and recovered at the end of hemodialysis. (3) LLMWUFH: gbACT at the arterial circuit was significantly increased only at 2 h of hemodialysis. CR at the arterial circuit and the venous circuit at 2 h of hemodialysis were significantly decreased and recovered when hemodialysis finished. (4) HH and HLMWH: gbACT were significantly increased and CR were rapidly decreased at both the arterial circuit and venous circuit at 2 h of hemodialysis.

 

CONCLUSION: Low-dose heparin was effective and safe as anticoagulant in hemodialysis. Low-dose low-molecular-weight heparin was efficient in anticoagulation to some extent. However, High-dose low-molecular-weight heparin, high-dose heparin and flushing with heparinized saline may increase the risk of hemorrhage. 

PMID: 20356555 [PubMed - indexed for MEDLINE]


Appropriate Dosage Of Unfraction Heparin And Low Molecular Weight Heparin In Hemodialysis Patients www.lifediagnostica.com ACT Machine Sonoclot

Comments

Popular posts from this blog

Thromboelastography TEG 5000 ROTEM TEMA Sonoclot Specifications for Tender

Instrument to measure changes in impendence to movement of a vibrating probe in the developing clot. Instrument with Microprocessor controlled electro-mechanical visco-elastic coagulation monitor for determination of coagulation real time haemostasis and end-points in whole blood, citrated whole blood and plasma samples. Instrument with Technology for detecting initial fibrin and monitoring the clot formation process ·        Instrument with Single Channel instrument for General Hemostasis and Platelet Function Analysis. POC instrument. Compact instrument for mobility. Results to be displayed on the instrument also. Instrument with Automated Process, without the use of pipettes to run samples. ·        Instrument with following functions: ·        ACT testing for anticoagulant Management. ·        Numerical value for platelet function on a scale of 0 to 5. ·        Heparin monitoring (ACT) and blood product managemen

ACT Machine, Activated Clotting Time Machine, www.lifediagnostica.com

Sonoclot ACT Machine Fondaparinux Monitoring

Fondaparinux is a new anticoagulant that interacts with antithrombin III and activated coagulation factor X resulting in an inhibition of the coagulation system. It has been successful in doses of 2.5 mg for thromboprophylaxis as well as in higher therapeutic doses of 5- 7.5 mg. No optimal method for monitoring the effects of fondaparinux has been proposed. The aim of the present study was to investigate whether a viscoelastic coagulation analyzer, the Sonoclot (Sienco, Denv er, Colorado, USA), could be used for in- vitro monitoring of fondaparinux.  Different concentrations of fondaparinux were added in-vitro to whole blood taken from eight volunteers. The blood samples mixed with the various amounts of fondaparinux were analyzed using the Sonoclot. The whole- blood activated partial thromboplastin time with the Hemochron Jr (IT C, Edison, New Jersey , USA) was used as the reference coagulation analysis. All analyses were started expeditiously , within 30 s from sampling, and were per